MG patient registry to track long-term experiences and treatment patterns
Official title: AXIS Autoimmune Neurology Registry
Run by Autoimmune Neurology Alliance · NCT07761026 · Data updated 2026-11-12
This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Autoimmune Neurology Alliance Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Framingham, Massachusetts) |
| Status | Recruiting |
| Started | March 19, 2026 |
| Main results expected | March 2036 |
| Study ends | March 2036 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT07761026 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults in the United States with physician-confirmed myasthenia gravis who can provide consent and participate remotely.
✕Probably not a fit
Patients who do not contribute data or who discontinue participation may not directly benefit from the registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The AXIS Autoimmune Neurology Registry is a prospective, longitudinal, observational collection of health information from adults with autoimmune neurological disorders, starting with myasthenia gravis. Participants enroll remotely, complete monthly MG surveys, and may share medical records to help researchers understand natural history and real-world management. The study does not assign treatments or alter standard care. Data include diagnosis details, MG type (ocular vs generalized), demographics, prior tests and treatments, antibody testing, and imaging findings when available. The registry may expand to other autoimmune neurological conditions in the future and is designed to minimize participant burden by using online and mobile app participation.
Why it matters
Potential benefit: If successful, the registry could improve understanding of MG progression and real-world treatment patterns to inform patient care and future research.
How similar studies have gone: Previous patient registries in autoimmune neurology have generated insights into disease course and treatment effects, supporting the potential value of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Physician-confirmed diagnosis of myasthenia gravis (MG) * Willing and legally able to provide consent * Lives in the United States Exclusion Criteria: * Unwilling or unable to provide consent or comprehend and complete questionnaires * Cognitively impaired adults/unable to comprehend or understand the consent or overall study information
Where it's running
-
Alira Health - Virtual/Remote Site - Can Be Completed 100% Online - All US Residents Accepted
Framingham, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Jared R Adams, MD, PhD — Alira Health
- Study coordinator: AXIS Patient Registry Team
- Email: support@axispatientregistry.com
- Phone: 765-632-2517
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry for people living with Myasthenia Gravis
This study is collecting information from people with Myasthenia Gravis to understand their experiences, symptoms, and treatments over time.
-
Empasiprubart IV in people with AChR-Ab positive generalized myasthenia gravis
This study tests whether empasiprubart given by IV can help people with AChR-Ab positive generalized myasthenia gravis feel better and have fewer symptoms.
-
Efgartigimod for hospitalized myasthenia gravis exacerbations or crisis
This will try giving efgartigimod in the hospital to see if it helps adults with AChR‑positive generalized myasthenia gravis who are admitted for a severe worsening of symptoms.
-
ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis
This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.
-
Adding empasiprubart to efgartigimod for AChR-antibody positive generalized myasthenia gravis
This trial will test whether adding empasiprubart to efgartigimod infusions helps people with AChR-antibody positive generalized myasthenia gravis who have only had a partial response to efgartigimod.
-
Evaluating NMD670 for treating Myasthenia Gravis in adults
This study is testing if a new medication called NMD670 can help adults with Myasthenia Gravis feel better by comparing different doses to a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.